Early access
Sign in
Taking people in United StatesPhase 2

YB-101 injections for adults with Graves' disease, compared with placebo

Tests YB-101 against placebo for safety and thyroid effects in Graves' disease.

Key facts

Who runs it
Yarrow Bioscience, Inc.
Where
Amarillo, Bowling Green, Cary, Conroe, Dallas, Durham, Edinburg, El Paso, Flint, Fort Worth, Gilbert, Houston, Humble, La Mesa, Livonia, Macon, Miami Lakes, Niagara Falls, Ocoee, Omaha, Orchard Park, Palm Harbor, Phoenix, Sacramento, San Francisco, Sarasota, Sayre, Torrance, and Tucson, United StatesSee the 29 sitesAlso in 1 other country, 3 sites
Trial code
Registry title
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Status
Recruiting
Phase
Phase 2
People taking part
232 people, planned
Started
10 Jun 2026
Expected to end
Sept 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Experimental: YB-101
  • Placebo YB-101
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves' disease, an overactive thyroid caused by the immune system. It tests YB-101 against a placebo (dummy injection).

Age
18 Years and older
Sex
All
Disease stage
Graves' disease confirmed by thyroid-stimulating hormone receptor antibodies (TRAbs). People can join with a known diagnosis of TED (thyroid eye disease) or with no sign of TED at the screening eye exam.
Earlier treatment
People cannot have had radioactive iodine (RAI) therapy or total removal of the thyroid. No levothyroxine, desiccated thyroid extract or T3 within 6 weeks before screening. No teprotumumab now or within 15 weeks before screening.
Biomarker or test result
Thyroid-stimulating hormone receptor antibodies (TRAbs) present, from medical history or a screening lab test.

Main reasons for not taking part

  • Earlier radioactive iodine (RAI) therapy or total thyroidectomy
  • Levothyroxine, desiccated thyroid extract or T3 within 6 weeks before screening
  • Teprotumumab now or within 15 weeks before screening
  • Overactive thyroid from another cause, such as toxic adenoma or toxic multinodular goiter, within 6 months before screening
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment
  • Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening
  • Additional inclusion criteria are defined in the protocol

Who cannot take part

  • Previously treated with radioactive iodine (RAI) therapy or underwent total thyroidectomy
  • Received any dose of levothyroxine, desiccated thyroid extract, or T3 within 6 weeks before screening
  • Current treatment with teprotumumab or exposure to teprotumumab within 15 weeks prior to screening
  • History of hyperthyroidism not caused by Graves' disease (eg. toxic adenoma, or toxic multinodular goiter) within 6 months before the screening visit
  • Pregnant or lactating women
  • Additional exclusion criteria are defined in the protocol

Where in United States

Also in 1 other country, 3 sites

  • Amarillo, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Bowling Green, KentuckyHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Cary, North CarolinaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Conroe, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Dallas, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Durham, North CarolinaHospital not named in the registryContact: Victoria Lacasse, MDNot yet recruiting
  • Edinburg, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • El Paso, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Flint, MichiganHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Fort Worth, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Gilbert, ArizonaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Houston, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Humble, TexasHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • La Mesa, CaliforniaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Livonia, MichiganHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Macon, GeorgiaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Miami Lakes, FloridaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Niagara Falls, New YorkHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Ocoee, FloridaHospital not named in the registryContact: Victoria Lacasse, MDNot yet recruiting
  • Omaha, NebraskaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Orchard Park, New YorkHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Palm Harbor, FloridaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Phoenix, ArizonaHospital not named in the registryContact: Victoria Lacasse, MDNot yet recruiting
  • Sacramento, CaliforniaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • San Francisco, CaliforniaHospital not named in the registryContact: Victoria Lacasse, MDNot yet recruiting
  • Sarasota, FloridaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Sayre, PennsylvaniaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Torrance, CaliforniaHospital not named in the registryContact: Victoria Lacasse, MDTaking people
  • Tucson, ArizonaHospital not named in the registryContact: Victoria Lacasse, MDTaking people

About the trial

What the trial wants to find out

This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.

Read full original descriptionShow less

The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2.

Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.

The 2 groups in the trial

  • YB-101Treatment being tested

    In Part 1, participants will receive YB-101 via subcutaneous injection. Part 2 participants will receive YB-101 via subcutaneous injection.

    Treatment: Experimental: YB-101

  • Placebo YB-101Placebo, for comparison

    In Part 1, participants will receive placebo via subcutaneous injection. Part 2 participants will receive placebo via subcutaneous injection.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease
Plain-language title
YB-101 injections for adults with Graves' disease, compared with placeboGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
30 October 2026